Ontology highlight
ABSTRACT:
SUBMITTER: Venur VA
PROVIDER: S-EPMC5395273 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Venur Vyshak Alva VA Joshi Monika M Nepple Kenneth G KG Zakharia Yousef Y
Drug design, development and therapy 20170411
Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 ...[more]